October 25, 2018

Novocure Reports Third Quarter 2018 Financial Results and Provides Company Update

Quarterly net revenues of $64.8 million, representing 29 percent growth versus the third quarter 2017 and 5 percent growth versus the second quarter 2018 Humanitarian device exemption (HDE) application submitted to FDA for approval in malignant pleural mesothelioma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today reported… Read More
learn more
October 25, 2018

Novocure Reports Third Quarter 2018 Financial Results and Provides Company Update

Quarterly net revenues of $64.8 million, representing 29 percent growth versus the third quarter 2017 and 5 percent growth versus the second quarter 2018 Humanitarian device exemption (HDE) application submitted to FDA for approval in malignant pleural mesothelioma ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today reported… Read More
learn more
October 24, 2018

Novocure Founder Professor Yoram Palti and Director Louis J. Lavigne, Jr. Retire from Board of Directors

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today the retirement of Novocure founder Professor Yoram Palti, MD, PhD, and director Louis J. Lavigne, Jr. from the board of directors effective October 24, 2018. Professor Palti invented Tumor Treating Fields and founded Novocure in 2000. He serves… Read More
learn more
October 24, 2018

Novocure Founder Professor Yoram Palti and Director Louis J. Lavigne, Jr. Retire from Board of Directors

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today the retirement of Novocure founder Professor Yoram Palti, MD, PhD, and director Louis J. Lavigne, Jr. from the board of directors effective October 24, 2018. Professor Palti invented Tumor Treating Fields and founded Novocure in 2000. He serves… Read More
learn more
October 23, 2018

Higher Delivered Dose of Tumor Treating Fields to Tumor Bed Associated with Improved Overall Survival in Newly Diagnosed Glioblastoma

Post-hoc analysis of EF-14 phase 3 pivotal trial demonstrated that power loss density and electric field intensity were associated with improved overall survival, independent of compliance This is the first analysis to quantify the delivered dose of Tumor Treating Fields, defined as a function of both power loss… Read More
learn more
October 23, 2018

Higher Delivered Dose of Tumor Treating Fields to Tumor Bed Associated with Improved Overall Survival in Newly Diagnosed Glioblastoma

Post-hoc analysis of EF-14 phase 3 pivotal trial demonstrated that power loss density and electric field intensity were associated with improved overall survival, independent of compliance This is the first analysis to quantify the delivered dose of Tumor Treating Fields, defined as a function of both power loss… Read More
learn more
October 22, 2018

Pancreatology Publishes Results of the PANOVA Phase 2 Pilot Trial in Advanced Pancreatic Cancer Suggesting Improved Survival of Patients Treated with Tumor Treating Fields

The Tumor Treating Fields plus gemcitabine and nab-paclitaxel patient cohort showed progression free and one-year survivals that were more than double those of the gemcitabine and nab-paclitaxel-treated historical control ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the results of its PANOVA phase 2 pilot trial… Read More
learn more
October 22, 2018

Pancreatology Publishes Results of the PANOVA Phase 2 Pilot Trial in Advanced Pancreatic Cancer Suggesting Improved Survival of Patients Treated with Tumor Treating Fields

The Tumor Treating Fields plus gemcitabine and nab-paclitaxel patient cohort showed progression free and one-year survivals that were more than double those of the gemcitabine and nab-paclitaxel-treated historical control ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the results of its PANOVA phase 2 pilot trial… Read More
learn more
October 18, 2018

Novocure Announces that the Medicare DME MACs Have Accepted the Local Coverage Determination Reconsideration Request for Optune®

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the durable medical equipment (DME) Medicare administrative contractors (MACs) have accepted our local coverage determination (LCD) reconsideration request for the treatment of newly diagnosed glioblastoma (GBM) and plan to take steps to publish a final LCD for newly diagnosed… Read More
learn more
October 18, 2018

Novocure Announces that the Medicare DME MACs Have Accepted the Local Coverage Determination Reconsideration Request for Optune®

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the durable medical equipment (DME) Medicare administrative contractors (MACs) have accepted our local coverage determination (LCD) reconsideration request for the treatment of newly diagnosed glioblastoma (GBM) and plan to take steps to publish a final LCD for newly diagnosed… Read More
learn more